<DOC>
	<DOCNO>NCT02660645</DOCNO>
	<brief_summary>Registry study gather information current use Blue Light Cystoscopy Cysview ( BLCC ) urologists ' practice .</brief_summary>
	<brief_title>Blue Light Cystoscopy With Cysview® Registry</brief_title>
	<detailed_description>Data capture specific patient type undergo Blue Light Cystoscopy Cysview know suspect non-muscle invasive bladder cancer . Specific clinical question ask . 1 . What incremental detection rate Blue Light Cystoscopy Cysview conventional white light cystoscopy seven ( 7 ) patient population ? Does translate low recurrence/progression rate ? 2 . How six ( 6 ) tumor variable use European Association Urology ( EAU ) risk table ( primary/secondary , recurrence rate , size , multifocality , grade , history carcinoma situ ( CIS ) ) 6 affect incremental rate ? 3 . How abnormal cytology positive negative fluorescent situ hybridization ( FISH ) affect likelihood Blue Light Cystoscopy Cysview detect cancer white light ? 4 . What performance characteristic Blue Light Cystoscopy Cysview within eight ( 8 ) week Bacillus Calmette-Guérin ( BCG ) respect improve tumor detection false positive rate compare conventional white light cystoscopy ? 5 . What incremental Blue Light Cystoscopy Cysview detection rate random bladder biopsy alone patient evaluate routine three month restaging ( group 4 ) occult disease ( group 5 ) ? 6 . What performance characteristic Blue Light Cystoscopy Cysview repeat Blue Light Cystoscopy Cysview evaluation respect improve tumor detection , false positive rate safety compare conventional white light ? 7 . Does abnormal urinalysis help identify patient inflammation likely false positive Blue Light Cystoscopy Cysview result ? 8 . What practical learning curve become `` proficient '' Blue Light Cystoscopy Cysview ? 9 . What overall false positive rate Blue Light Cystoscopy Cysview ? 10 . Can Blue Light Cystoscopy Cysview make resection complete ? If yes , due improve margin and/or additional tumor see blue light ? The Blue Light Cystoscopy Cysview Registry web-based program support Global Vision Technologies . Data capture longitudinally two ( 2 ) year patient enrol site . Each center enter respective site 's patient data electronically .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Adult &gt; 18 year old Suspected known nonmuscle invasive bladder cancer basis prior cystoscopy Porphyria Gross hematuria Known hypersensitivity hexaminolevulinate aminolevulinate derivative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cysview</keyword>
	<keyword>Hexaminolevulinate</keyword>
	<keyword>Hexvix</keyword>
	<keyword>NMIBC</keyword>
	<keyword>BLCC</keyword>
	<keyword>Blue Light Cystoscopy Cysview</keyword>
	<keyword>Cystoscopy</keyword>
	<keyword>TURBT</keyword>
	<keyword>TUR</keyword>
	<keyword>Fluorescent cystoscopy</keyword>
	<keyword>Non-muscle invasive bladder cancer ( NMIBC )</keyword>
	<keyword>Transurethral resection ( TUR )</keyword>
</DOC>